HomeComparePEYUF vs ABBV

PEYUF vs ABBV: Dividend Comparison 2026

PEYUF yields 4.90% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEYUF wins by $5519.67M in total portfolio value
10 years
PEYUF
PEYUF
● Live price
4.90%
Share price
$19.53
Annual div
$0.96
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5519.77M
Annual income
$5,311,738,998.81
Full PEYUF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PEYUF vs ABBV

📍 PEYUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPEYUFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PEYUF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PEYUF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PEYUF
Annual income on $10K today (after 15% tax)
$416.92/yr
After 10yr DRIP, annual income (after tax)
$4,514,978,148.99/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PEYUF beats the other by $4,514,957,092.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PEYUF + ABBV for your $10,000?

PEYUF: 50%ABBV: 50%
100% ABBV50/50100% PEYUF
Portfolio after 10yr
$2759.94M
Annual income
$2,655,881,885.28/yr
Blended yield
96.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PEYUF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.0
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PEYUF buys
0
ABBV buys
0
No recent congressional trades found for PEYUF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPEYUFABBV
Forward yield4.90%3.06%
Annual dividend / share$0.96$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$5519.77M$102.3K
Annual income after 10y$5,311,738,998.81$24,771.77
Total dividends collected$5505.16M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: PEYUF vs ABBV ($10,000, DRIP)

YearPEYUF PortfolioPEYUF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,681$980.99$11,550$430.00+$131.00PEYUF
2$14,641$2,141.86$13,472$627.96+$1.2KPEYUF
3$20,683$5,017.82$15,906$926.08+$4.8KPEYUF
4$35,381$13,250.19$19,071$1,382.55+$16.3KPEYUF
5$80,224$42,366.59$23,302$2,095.81+$56.9KPEYUF
6$265,398$179,557.70$29,150$3,237.93+$236.2KPEYUF
7$1,394,277$1,110,301.25$37,536$5,121.41+$1.36MPEYUF
8$12,394,691$10,902,815.07$50,079$8,338.38+$12.34MPEYUF
9$194,426,163$181,163,842.84$69,753$14,065.80+$194.36MPEYUF
10$5,519,774,993$5,311,738,998.81$102,337$24,771.77+$5519.67MPEYUF

PEYUF vs ABBV: Complete Analysis 2026

PEYUFStock

Peyto Exploration & Development Corp. engages in the exploration, development, and production of oil and natural gas, and natural gas liquids in Deep Basin of Alberta. As of December 31, 2021, it had a total proved plus probable reserves of 904 million barrels of oil equivalent. The company was formerly known as Peyto Energy Trust and changed its name to Peyto Exploration & Development Corp. in January 2011. Peyto Exploration & Development Corp. was founded in 1998 and is headquartered in Calgary, Canada.

Full PEYUF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PEYUF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PEYUF vs SCHDPEYUF vs JEPIPEYUF vs OPEYUF vs KOPEYUF vs MAINPEYUF vs JNJPEYUF vs MRKPEYUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.